Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
25 Sep 2021
Historique:
received: 21 10 2020
accepted: 06 09 2021
entrez: 26 9 2021
pubmed: 27 9 2021
medline: 21 10 2021
Statut: epublish

Résumé

Patient medical out-of-pocket expenses are thought to be rising worldwide yet data describing trends over time is scant. We evaluated trends of out-of-pocket expenses for patients in Australia with one of five major cancers in the first-year after diagnosis. Participants from the QSKIN Sun and Health prospective cohort Study with a histologically confirmed breast, colorectal, lung, melanoma, or prostate cancer diagnosed between 2011 and 2015 were included (n = 1965). Medicare claims data on out-of-pocket expenses were analysed using a two-part model adjusted for year of diagnosis, health insurance status, age and education level. Fisher price and quantity indexes were also calculated to assess prices and volumes separately. On average, patients with cancer diagnosed in 2015 spent 70% more out-of-pocket on direct medical expenses than those diagnosed in 2011. Out-of-pocket expenses increased significantly for patients with breast cancer (mean AU$2513 in 2011 to AU$6802 in 2015). Out-of-pocket expenses were higher overall for individuals with private health insurance. For prostate cancer, expenses increased for those without private health insurance over time (mean AU$1586 in 2011 to AU$4748 in 2014) and remained stable for those with private health insurance (AU$4397 in 2011 to AU$5623 in 2015). There were progressive increases in prices and quantities of medical services for patients with melanoma, breast and lung cancer. For all cancers, prices increased for medicines and doctor attendances but fluctuated for other medical services. Out-of-pocket expenses for patients with cancer have increased substantially over time. Such increases were more pronounced for women with breast cancer and those without private health insurance. Increased out-of-pocket expenses arose from both higher prices and higher volumes of health services but differ by cancer type. Further efforts to monitor patient out-of-pocket costs and prevent health inequities are required.

Sections du résumé

BACKGROUND BACKGROUND
Patient medical out-of-pocket expenses are thought to be rising worldwide yet data describing trends over time is scant. We evaluated trends of out-of-pocket expenses for patients in Australia with one of five major cancers in the first-year after diagnosis.
METHODS METHODS
Participants from the QSKIN Sun and Health prospective cohort Study with a histologically confirmed breast, colorectal, lung, melanoma, or prostate cancer diagnosed between 2011 and 2015 were included (n = 1965). Medicare claims data on out-of-pocket expenses were analysed using a two-part model adjusted for year of diagnosis, health insurance status, age and education level. Fisher price and quantity indexes were also calculated to assess prices and volumes separately.
RESULTS RESULTS
On average, patients with cancer diagnosed in 2015 spent 70% more out-of-pocket on direct medical expenses than those diagnosed in 2011. Out-of-pocket expenses increased significantly for patients with breast cancer (mean AU$2513 in 2011 to AU$6802 in 2015). Out-of-pocket expenses were higher overall for individuals with private health insurance. For prostate cancer, expenses increased for those without private health insurance over time (mean AU$1586 in 2011 to AU$4748 in 2014) and remained stable for those with private health insurance (AU$4397 in 2011 to AU$5623 in 2015). There were progressive increases in prices and quantities of medical services for patients with melanoma, breast and lung cancer. For all cancers, prices increased for medicines and doctor attendances but fluctuated for other medical services.
CONCLUSION CONCLUSIONS
Out-of-pocket expenses for patients with cancer have increased substantially over time. Such increases were more pronounced for women with breast cancer and those without private health insurance. Increased out-of-pocket expenses arose from both higher prices and higher volumes of health services but differ by cancer type. Further efforts to monitor patient out-of-pocket costs and prevent health inequities are required.

Identifiants

pubmed: 34563142
doi: 10.1186/s12885-021-08756-x
pii: 10.1186/s12885-021-08756-x
pmc: PMC8466922
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1055

Subventions

Organisme : National Health and Medical Research Council
ID : 1073898
Organisme : National Health and Medical Research Council
ID : 1058522

Informations de copyright

© 2021. The Author(s).

Références

Aust J Rural Health. 2011 Dec;19(6):298-305
pubmed: 22098213
Support Care Cancer. 2015 Mar;23(3):889-98
pubmed: 25337681
Eur J Cancer Care (Engl). 2017 Jan;26(1):
pubmed: 26423576
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 28771857
J Pain Symptom Manage. 2019 Mar;57(3):646-660.e1
pubmed: 30550833
Health Econ Rev. 2019 Mar 11;9(1):10
pubmed: 30859357
Health Econ. 2017 Apr;26(4):528-535
pubmed: 26913491
Med J Aust. 2018 Jun 18;208(11):497
pubmed: 29902395
Patient. 2020 Jun;13(3):363-373
pubmed: 32072460
Oncologist. 2014 Apr;19(4):414-20
pubmed: 24668333
Aust J Prim Health. 2017 Apr;23(1):15-22
pubmed: 28442033
Support Care Cancer. 2017 Sep;25(9):2733-2741
pubmed: 28341973
Health Econ. 2011 Aug;20(8):897-916
pubmed: 20799344
J Clin Oncol. 2016 Mar 20;34(9):980-6
pubmed: 26811521
J Med Person. 2013 Aug 1;11(2):
pubmed: 24349677
Cancer. 2013 Oct 15;119(20):3710-7
pubmed: 23907958
Health Policy. 2017 Apr;121(4):426-433
pubmed: 28237388
Aust N Z J Public Health. 2016 Apr;40(2):154-8
pubmed: 26558736
Aust J Prim Health. 2018 Jan;24(6):530-536
pubmed: 30463662
Int J Epidemiol. 2012 Aug;41(4):929-929i
pubmed: 22933644
BMC Public Health. 2018 Apr 6;18(1):375
pubmed: 29621995
Support Care Cancer. 2018 May;26(5):1357-1359
pubmed: 29435714
Intern Med J. 2014 May;44(5):458-63
pubmed: 24612257
BMC Cancer. 2019 Mar 8;19(1):214
pubmed: 30849964
Patient. 2017 Jun;10(3):295-309
pubmed: 27798816
Aust N Z J Public Health. 2020 Jun;44(3):219-226
pubmed: 32311194
Annu Rev Public Health. 2018 Apr 1;39:489-505
pubmed: 29328879
BMC Health Serv Res. 2020 May 6;20(1):380
pubmed: 32375869
Support Care Cancer. 2018 Oct;26(10):3543-3552
pubmed: 29704109

Auteurs

Astrid J Rodriguez-Acevedo (AJ)

QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia.

Raymond J Chan (RJ)

Queensland University of Technology (QUT), School of Nursing and Cancer and Palliative Care Outcomes Centre, Kelvin Grove, Brisbane, Q4059, Australia.
Princess Alexandra Hospital, Division of Cancer Services, Wollonggabba , Brisbane, Q4102, Australia.

Catherine M Olsen (CM)

QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia.
The University of Queensland, Faculty of Medicine, Herston, Brisbane, Q4006, Australia.

Nirmala Pandeya (N)

QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia.

David C Whiteman (DC)

QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia.

Louisa G Gordon (LG)

QIMR Berghofer Medical Research Institute, Population Health Department, Herston, Brisbane, Q4006, Australia. louisa.gordon@qimrberghofer.edu.au.
Queensland University of Technology (QUT), School of Nursing and Cancer and Palliative Care Outcomes Centre, Kelvin Grove, Brisbane, Q4059, Australia. louisa.gordon@qimrberghofer.edu.au.
The University of Queensland, Faculty of Medicine, Herston, Brisbane, Q4006, Australia. louisa.gordon@qimrberghofer.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH